Shore Capital Reiterates AstraZeneca (AZNCF) Buy Recommendation

Shore Capital reiterated a "Buy" recommendation for AstraZeneca (OTCPK:AZNCF) on November 6, 2025, setting an average one-year price target of $183.51, which implies a 15.14% upside from its current $159.38. This positive analyst outlook comes despite projected annual revenue decreasing by 10.20% to $52,200MM and a non-GAAP EPS forecast of $9.12. Institutional sentiment appears mixed, with the number of funds holding AZNCF declining by 5.88% and total shares owned by institutions decreasing by 8.86%, even as the average portfolio weight dedicated to the stock increased by 16.38%.

Analysis

Shore Capital reiterated a "Buy" recommendation for AstraZeneca (OTCPK:AZNCF) on November 6, 2025, setting an average one-year price target of $183.51. This target implies a 15.14% upside from the latest reported closing price of $159.38, indicating a positive outlook from the analyst firm.

This optimistic analyst view contrasts with the projected financial performance, as AstraZeneca's annual revenue is forecast to decrease by 10.20% to $52,200MM. The projected annual non-GAAP EPS is $9.12, suggesting potential top-line challenges despite the positive rating.

Institutional investor sentiment appears mixed; the number of funds reporting positions in AZNCF decreased by 5.88% (4 owners), and total shares owned by institutions declined by 8.86% to 16,046K shares. However, the average portfolio weight dedicated to AZNCF by these funds increased by 16.38% to 1.05%.

This divergence suggests that while some institutions are reducing or exiting positions, those who remain are allocating a larger proportion of their portfolios to AstraZeneca, indicating a consolidation of conviction among a smaller group of holders.

Key Decisions for Investors

• Investors should critically evaluate the analyst's "Buy" recommendation and 15.14% upside potential in light of the projected 10.20% annual revenue decrease.
• Monitor the underlying reasons for the projected revenue decline and assess its potential impact on the company's long-term growth trajectory and profitability.
• Observe institutional ownership trends, specifically the increase in average portfolio weight among remaining holders, as this could signal higher conviction despite a reduction in overall institutional share count.